

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---------------------------|---|---|--|--|
| Infectious disease | | | | |
| Cytomegalovirus (CMV) | Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335) | <p>Studies in mice suggest antagonizing NCR1 could help treat CMV. Mice with a loss-of-function mutation in the <i>Ncr1</i> gene had greater NK cell activity and higher resistance to murine CMV infection than wild-type controls. NK cells from wild-type mice treated with an anti-NCR1 mAb had greater NK cell activity than mice receiving control mAbs. Next steps include testing anti-NCR1 mAbs in mouse models of diseases modulated by NK cell activity, including influenza and cancer.</p> <p>Innate Pharma S.A., which was cofounded by study author Eric Vivier, is evaluating therapeutics that target NCR1.</p> <p>SciBX 5(4); doi:10.1038/scibx.2012.99 Published online Jan. 26, 2012</p> | Patent filed; licensing status undisclosed | <p>Narini-Mancinelli, E. <i>et al. Science</i>; published online Jan. 20, 2012; doi:10.1126/science.1215621</p> <p>Contact: Sophie Ugolini, Aix-Marseille University, Marseille, France e-mail: ugolini@ciml.univ-mrs.fr</p> <p>Contact: Eric Vivier, same affiliation as above e-mail: vivier@ciml.univ-mrs.fr</p> |